Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Measles, mumps, and rubella virus antigens collectively refers to the critical surface proteins of three distinct viruses—measles (hemagglutinin [H] and fusion [F] proteins), mumps (fusion protein [F] and hemagglutinin-neuraminidase [HN]), and rubella (envelope glycoprotein E1)—that serve as chief immunogens driving protective responses following infection or vaccination. These antigens mediate viral entry by binding to cellular receptors and fusing viral and host membranes, and are targeted by neutralizing antibodies in both natural immunity and immunization strategies. While grouped in the context of the MMR vaccine or combined serological testing, they are structurally and functionally distinct and should be considered individually in molecular and pharmacological studies.
Induction of adaptive immunity by presenting viral antigens, stimulating B and T cell responses, and fostering neutralizing antibody responses that block viral entry and replication
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Measles virus antigen, Mumps virus antigen, Rubella virus antigen.